Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
Key Takeaways
- Retatrutide is an investigational triple hormone receptor agonist (GLP-3R). It activates GLP-1, GIP, and glucagon receptors and produces greater weight loss than single or dual agonists in trials.
- In the Phase 3 TRIUMPH-1 trial, the 12 mg dose produced 28.3% mean weight loss at 80 weeks. Participants with BMI ≥35 who continued to 104 weeks lost an average of 30.3% of body weight.1
- Secondary benefits include large reductions in liver fat (up to 82.4%), triglycerides (up to 41%), blood pressure, and osteoarthritis pain.1 These changes largely reflect the degree of weight loss.
- Retatrutide remains investigational and is not FDA-approved. Unregulated online products carry significant safety risks when used without medical supervision.
- Patients interested in GLP-3R therapy should work with a qualified physician for supervised treatment. To review your health profile and goals, schedule your consultation at Mirror Plastic Surgery.
Physician Background And How This Report Was Created
Dr. Akash Chandawarkar, MD, is the founder of Mirror Plastic Surgery and the lead physician for all peptide therapy protocols at the practice. He graduated with Honors from Harvard Medical School through the Harvard-MIT Division of Health Sciences and Technology. He then completed a seven-year integrated plastic and reconstructive surgery residency at Johns Hopkins University and holds a Stanford Biodesign Innovation Fellowship, which trains physicians to identify unmet clinical needs and develop evidence-based solutions.
Dr. Akash’s peptide therapy practice relies on comprehensive lab analysis, personalized protocols, and ongoing concierge support. Each protocol is built around the patient’s labs and physiology and remains under direct medical supervision. This report reflects the perspective of a physician who actively treats patients with peptide therapies and understands both the clinical science and the real-world safety issues that generic health content often overlooks.
Discuss your health profile with Dr. Chandawarkar to see whether GLP-3R therapy fits your goals.
What GLP-3R Means In The Context Of Retatrutide
GLP-3R is an informal term for triple hormone receptor agonists like retatrutide. These drugs activate GLP-1, GIP, and glucagon receptors at the same time. GLP-3R is not an official medical classification and is unrelated to thyroid hormone T3, which many people confuse with this term. Researchers are studying these agents for weight loss and broader metabolic health.
The “GLP-3” or “GLP-3R” label appears frequently in media and social channels. The more accurate scientific description is “triple agonist” or “triple hormone receptor agonist”, because the drug mimics three distinct hormones rather than a third member of the glucagon-like peptide family.
GLP-3R Vs. GLP-1 Vs. GLP-2: Key Differences
Each receptor class plays a different role in the body:
- GLP-1 is the target of drugs like semaglutide (Ozempic/Wegovy). It regulates appetite and slows gastric emptying, which creates the “I feel full” effect.
- GLP-2 supports gut and intestinal health and is mainly studied for mucosal repair rather than weight loss.
- Triple agonists (GLP-3R) like retatrutide add GIP and glucagon receptor activation to GLP-1 agonism. This multi-pathway approach produces substantially greater weight loss than single or dual agonists in clinical trials.
How GLP-3R Works In The Body
Retatrutide is an investigational, once-weekly triple hormone receptor agonist that activates receptors for GIP, GLP-1, and glucagon. Each receptor contributes a specific effect:
- GLP-1 receptor activation reduces appetite and slows gastric emptying, which lowers caloric intake.
- GIP receptor activation improves insulin sensitivity and helps the body process sugars and fats more efficiently.
- Glucagon receptor activation is the main feature that sets retatrutide apart from currently approved therapies. It increases energy expenditure and promotes fat breakdown. Retatrutide therefore becomes the first weight loss compound that clearly raises resting energy expenditure instead of only reducing energy intake.
Beyond raising energy expenditure, glucagon receptor activation may also help preserve lean muscle mass during weight loss. The body appears to burn fat preferentially for energy. Researchers still need dedicated body composition trials to confirm this effect.
Clinical Trial Evidence On Retatrutide
Researchers have evaluated retatrutide in a Phase 2 trial published in the New England Journal of Medicine and in multiple Phase 3 trials. In the Phase 2 trial (Jastreboff et al., 2023, NEJM), mean weight reductions at 48 weeks were −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg), compared with −2.1% for placebo.1
The Phase 3 TRIUMPH-1 trial enrolled 2,339 participants who received retatrutide 4 mg, 9 mg, 12 mg, or placebo for 80 weeks. Results by dose are summarized below.
| Dose | Mean Weight Loss | ≥25% Weight Loss | ≥30% Weight Loss |
|---|---|---|---|
| 4 mg | 19.0% (47.2 lbs) | 27.8% | 15.3% |
| 9 mg | 25.9% (64.4 lbs) | 52.9% | 37.9% |
| 12 mg | 28.3% (70.3 lbs) | 62.5% | 45.3% |
| Placebo | 2.2% (5.5 lbs) | 2.2% | 0.5% |
In a pre-specified blinded extension of TRIUMPH-1 for participants with a baseline BMI ≥35, those who continued retatrutide 12 mg through 104 weeks lost an average of 85.0 lbs (30.3%) of body weight.1 This level of weight reduction has historically occurred only with bariatric surgery.
Retatrutide also shows strong efficacy in patients with type 2 diabetes. In the Phase 3 TRANSCEND-T2D-1 trial, the 12 mg dose produced 16.8% mean weight loss at 40 weeks and A1C reductions of up to 2.0%.1
For context, the SURMOUNT-5 head-to-head trial showed tirzepatide reduced weight by −20.2% versus −13.7% for semaglutide at 72 weeks.1 These comparisons involve different study designs and populations, so clinicians interpret them cautiously.
Beyond The Scale: Additional Health Effects
Clinical trials show several secondary health improvements that track closely with the amount of weight patients lose on retatrutide.
- Blood sugar control: In TRANSCEND-T2D-1, up to 46% of participants reached an A1C below 5.7%, the threshold for normoglycemia, and up to 90% reached an A1C below 7.0%.1
- Liver fat reduction: A Phase 2 substudy in Nature Medicine (Sanyal et al., 2024) found that retatrutide 12 mg reduced liver fat by 82.4% at 24 weeks.1 In that study, 86% of participants achieved normal liver fat (<5%), which represents the largest liver-fat reductions reported in a metabolic drug trial.
- Cardiovascular risk factors: TRIUMPH-1 showed reductions of up to 41.0% in triglycerides, 24.2% in non-HDL cholesterol, and 12.3 mmHg in systolic blood pressure at 80 weeks.1
- Joint pain: Participants experienced up to a 73.1% reduction in knee osteoarthritis pain from baseline on the WOMAC pain subscale.1
- Sleep apnea: In those with moderate-to-severe obstructive sleep apnea, retatrutide reduced the apnea-hypopnea index by up to 60.6% at 80 weeks.1
Long-term cardiovascular outcome data from the TRIUMPH-Outcomes trial is still pending. For now, clinicians view these improvements as correlates of major weight loss rather than proven independent drug effects.
Side Effects And Safety Considerations
Gastrointestinal symptoms are the most common side effects with retatrutide. In TRIUMPH-1 at the 12 mg dose, nausea occurred in 42.4% of participants (vs. 14.8% with placebo), diarrhea in 32.0% (vs. 13.5%), constipation in 26.1% (vs. 10.9%), and vomiting in 25.3% (vs. 4.8%). These effects usually appear during dose escalation and tend to lessen as the body adapts.
Retatrutide also increases resting heart rate by about 5–10 beats per minute in a dose-dependent pattern. Heart rate peaks around week 24 and then partially normalizes. This effect relates to glucagon receptor activity and is larger than the 2–4 bpm increase seen with tirzepatide or the 1–4 bpm increase with semaglutide.
Trial protocols identified several hard contraindications. These include a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, a history of pancreatitis, active gallbladder disease, severe gastroparesis, and pregnancy. Because retatrutide is not yet FDA-approved, long-term safety data beyond 104 weeks is not available.
The Dangers Of Unregulated Online Purchases
A June 2026 CBS News investigation identified more than 120 websites selling or promoting retatrutide, including over 50 clinics staffed by licensed medical professionals. This activity continues despite the FDA stating that the drug “has not been found safe or effective for any condition” and “cannot be manufactured or distributed except for investigational use.”
An Eli Lilly spokesperson stated, “Anyone purporting to sell retatrutide to consumers is breaking the law,” and reported “thousands of illicit retatrutide posts and ads” to platforms. The scale of the problem appears clearly in poison center data. America’s Poison Centers recorded about 95 retatrutide exposure calls per month in the first four months of 2026, a 265% increase over the last four months of 2025.
The specific risks of purchasing retatrutide online include:
- No quality control or third-party batch testing, so purity and actual active content remain unknown
- Incorrect dosing with no professional titration or oversight
- Contamination from unregulated manufacturing environments
- No screening for contraindications or drug interactions
- No monitoring for side effects such as elevated heart rate or gastrointestinal complications
Why Medical Supervision Matters At Mirror Plastic Surgery
Mirror Plastic Surgery’s concierge care model provides physician-led oversight that online marketplaces and high-volume telemedicine platforms lack. Care starts with a 30–60 minute consultation with Dr. Akash Chandawarkar. During this visit, he reviews or orders a comprehensive lab panel that covers thyroid, liver, kidney, diabetes markers, and hormone levels. He then designs a personalized peptide protocol around the patient’s physiology and goals.
The practice sources peptides from reputable providers that perform rigorous batch testing. This approach supports product quality, purity, and accurate dosing. Patients receive 24/7 direct text access to Dr. Akash for ongoing support, dose adjustments, and refill requests. This level of oversight, which includes screening for contraindications, monitoring for side effects, and adjusting protocols over time, makes peptide therapy safer and more effective than unsupervised use.
Explore a supervised peptide plan with Mirror Plastic Surgery to see whether GLP-3R therapy aligns with your needs.
How To Access GLP-3R And Talk With Your Provider
Eli Lilly plans to submit an FDA application for retatrutide in the first quarter of 2027. Until approval occurs, the drug remains legally available only through registered clinical trials or expanded-access authorization. Any provider offering retatrutide outside a sanctioned trial is operating outside the law, as confirmed by the CBS News investigation and FDA statements.
When you evaluate any provider for peptide therapy, ask questions that clarify the level of care:
- What are the risks and benefits of this therapy for my specific health profile?
- What lab tests do you recommend before starting, and how will the results shape my protocol?
- How do you ensure product quality and purity, and do your suppliers provide batch testing documentation?
- What is your follow-up and monitoring plan, including how you track heart rate and gastrointestinal tolerance?
- What contraindications will you screen for before prescribing?
Key Takeaways And Conclusion
Retatrutide (GLP-3R) currently represents the most potent weight loss therapy studied in clinical trials. As detailed above, the 12 mg dose produced unprecedented weight loss, reaching about 30% in TRIUMPH-1. The triple agonist mechanism that targets GLP-1, GIP, and glucagon receptors delivers stronger results than single agonists like semaglutide and dual agonists like tirzepatide. Patients also see meaningful reductions in liver fat, triglycerides, blood pressure, and osteoarthritis pain.
Retatrutide remains an investigational therapy and is not yet FDA-approved, so legal access is limited to clinical trials and controlled programs. Medical supervision provides the safeguard that separates monitored, evidence-based care from a dangerous and illegal grey market.
Schedule a consultation at Mirror Plastic Surgery to review whether GLP-3R therapy fits your health history and weight loss goals.
Frequently Asked Questions
What Is The Difference Between GLP-1 And GLP-3?
GLP-1 drugs like semaglutide (Ozempic/Wegovy) act on a single receptor to reduce appetite and slow digestion. “GLP-3” is a casual term for triple agonists like retatrutide, which activate GLP-1, GIP, and glucagon receptors at the same time. The glucagon component raises resting energy expenditure, an effect that GLP-1 drugs do not provide. This added pathway helps explain why retatrutide produces up to 30% weight loss in trials, compared with about 15% for semaglutide and about 21% for tirzepatide in their Phase 3 programs.
Is GLP-3R The Same As Retatrutide?
Most people who say “GLP-3” or “GLP-3R” are referring to retatrutide. Retatrutide is Eli Lilly’s investigational triple hormone receptor agonist. The precise scientific term is “triple hormone receptor agonist” because the drug activates GLP-1, GIP, and glucagon receptors rather than a third glucagon-like peptide. Retatrutide is not yet FDA-approved and is only legally available through registered clinical trials or expanded-access authorization.
How Much Weight Can You Lose On GLP-3R?
In the Phase 3 TRIUMPH-1 trial, participants taking retatrutide 12 mg lost an average of 28.3% of body weight (70.3 lbs) over 80 weeks. At 104 weeks, participants with a baseline BMI ≥35 who stayed on the 12 mg dose lost an average of 30.3% (85.0 lbs). In the Phase 2 NEJM trial, the 12 mg dose produced 24.2% mean weight loss at 48 weeks.1 Individual results vary based on dose, physiology, adherence, and the quality of medical supervision during dose escalation.
What Are The Side Effects Of Retatrutide?
Gastrointestinal side effects are most common. In TRIUMPH-1 at the 12 mg dose, nausea occurred in 42.4%, diarrhea in 32.0%, constipation in 26.1%, and vomiting in 25.3% of participants, with much lower rates in the placebo group. These symptoms usually appear during titration and tend to ease over four to six weeks. Retatrutide also raises resting heart rate by about 5–10 beats per minute, peaking around week 24 and then partially normalizing. In TRIUMPH-1, 11.3% of participants on the 12 mg dose discontinued due to adverse events. A slower titration schedule, as used in Phase 3, improves tolerability compared with the steeper Phase 2 escalation.
Is GLP-3R Safe?
In clinical trials, serious adverse event rates for retatrutide were similar to placebo, around 4% in Phase 3 TRIUMPH studies. The drug has shown an acceptable safety profile across more than 5,000 participants through 68–80 weeks. As noted earlier, retatrutide is not yet FDA-approved, and data beyond 104 weeks is not available. The drug also carries class-level precautions seen with GLP-1 agonists, including warnings related to thyroid C-cell tumors in rodent studies, pancreatitis, and gallbladder disease. The greatest safety concern arises when people buy unregulated products online, which removes quality control, dosing oversight, and medical screening.
Disclaimers
This article is for informational purposes only and does not constitute medical advice. Results vary from person to person. GLP-3R peptides are considered investigational and are not FDA-approved. Always consult a board-certified physician before starting any peptide therapy.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
